Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for leg artery disease: minimally invasive procedures under study

NCT ID NCT04698304

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study looks at how well minimally invasive procedures (like balloons and stents) work for people with severe blockages in the leg arteries. It will track 1000 patients to see if these treatments restore blood flow and keep arteries open over time. The goal is to find the best approach for complex cases that are often left out of other studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,518 people

The number who actually took part.

Started

Dec 2020

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with TASC C, D femoropopliteal lesions who undergoing endovascular treatment

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients over 18 years old 2. Patients with Rutherford classification range from 3 to 6 3. If patients with both lower limbs meeting the inclusion criteria, both side of limb can be selected for this study 4. The guide wire should pass through the lesion of femoropopliteal artery, and further endovascular treatment is performed. In this study, we did not limit the methods of the guide wire passing through the target lesion 5. If the first-time endovascular treatment is failure, patients undergo endovascular treatment successfully at the second time, the patients can still be enrolled 6. For patients with aortoiliac artery lesions, they can be enrolled after the successful reconstruction of aortoiliac artery 7. Informed consent signed by patients Exclusion Criteria: 1. Patients who are unwilling or refuse to sign the informed consent form 2. Patients with acute and subacute lower extremity arterial thrombosis or arterial embolism 3. Patients with thromboangiitis obliterans 4. Patients with failure of endovascular treatment, and transferred to bypass surgery 5. Patients who underwent surgical atherectomy for common femoral artery occlusive lesions 6. Patients with known allergy to heparin, low molecular weight heparin and contrast agents 7. Patients who have been enrolled in other clinical trials in the past 3 months 8. Women during pregnancy and lactation 9. Patients with other diseases that may lead to difficulties in the trial or significantly shorten the life expectancy (\< 3 years), such as tumors, severe liver disease, cardiac insufficiency

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Femoropopliteal occlusive disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Renji Hospital

    Shanghai, Shanghai Municipality, 200127, China